Gout and Crystal Arthropathy

Gout is the most common inflammatory arthritis in adults, caused by deposition of monosodium urate (MSU) crystals in joints and soft tissues. It results from prolonged hyperuricemia leading to crystal formation when serum urate exceeds its saturation point of 6.8 mg/dL (404 micromol/L).

Understanding the pathophysiology of gout is essential for both diagnosis and management. The disease results from a complex interplay of uric acid metabolism, crystal formation, and inflammatory responses.

Uric Acid Metabolism

Crystal Formation

Inflammatory Response

NLRP3 Inflammasome activation:

1. MSU crystals are phagocytosed by macrophages
2. Crystals destabilize lysosomal membranes
3. Cathepsin B released into cytoplasm
4. NLRP3 inflammasome assembly triggered
5. Caspase-1 activation
6. Pro-IL-1beta cleaved to active IL-1beta
7. Massive inflammatory cascade initiated

Resolution:

• Acute attacks are self-limiting (7-14 days)
• Aggregated neutrophil extracellular traps (NETs) help resolve inflammation
• Coating of crystals by proteins reduces immunogenicity
• Anti-inflammatory macrophage phenotype emerges

The tophus is the pathological hallmark of chronic gout and the structure the surgeon excises - understanding what it actually is explains both its radiographic appearance and the principle that optimised urate-lowering therapy can dissolve it medically. A tophus is not a simple lump of crystal but an organised, chronic foreign-body granulomatous response to deposited monosodium urate.

Microscopic Zones

A mature tophus has three concentric zones:

Because the crystals are in equilibrium with the serum urate, tophi are reversible: sustained urate-lowering therapy below the saturation point (and below 5 mg/dL when tophi are present) lets them slowly dissolve. This is why many surgeons now favour debulking plus optimised medical therapy over aggressive wide excision, which risks an unclosable defect.

Acute Gouty Arthritis

Chronic Tophaceous Gout

Features:

• Tophi: Chalky deposits of MSU crystals in soft tissues
• Common locations: Fingers, olecranon bursa, Achilles tendon, ears
• Joint destruction: Erosive arthropathy with preserved joint space initially
• Tendon involvement: Can cause rupture (Achilles, patellar, extensor tendons)

Physical Examination

Laboratory Studies

Synovial fluid analysis (Gold Standard):

• MSU crystal identification under polarized microscopy
• Needle-shaped, negatively birefringent crystals
• WBC count: 10,000-70,000/microL (predominantly neutrophils)

View larger

View larger

Imaging

Plain Radiographs:

• Early: Soft tissue swelling, normal bone
• Established: Punched-out erosions with overhanging edges ("rat bite" or "mouse ear")
• Preserved joint space (unlike OA)
• Soft tissue tophi may calcify

View larger

The single most important mimic of acute gout is septic arthritis - the two can coexist, and a hot, swollen joint must be aspirated to exclude infection before attributing it to crystals.

Algorithm

View larger

Acute Attack Management

Urate-Lowering Therapy (ULT)

Colchicine appears throughout gout management - acute flares, prophylaxis when starting urate-lowering therapy, and perioperative cover - yet how it works and why it is dangerous in overdose are commonly examined.

Mechanism of Action

Colchicine is an anti-mitotic alkaloid that binds tubulin and prevents microtubule polymerisation. In gout this disrupts neutrophil function - chemotaxis, adhesion and motility - and impairs assembly and activation of the NLRP3 inflammasome, reducing IL-1beta-driven inflammation. It is anti-inflammatory only: it is not an analgesic and not urate-lowering, so it treats the crystal-induced inflammatory response but does nothing to the serum urate.

Toxicity

Drug Interactions

Colchicine is metabolised by CYP3A4 and is a substrate of the P-glycoprotein efflux transporter. Co-administration with strong CYP3A4 or P-glycoprotein inhibitors - clarithromycin and other macrolides, azole antifungals, ciclosporin, verapamil and diltiazem - raises colchicine levels and can precipitate life-threatening toxicity. The dose must be reduced, or colchicine avoided, in significant renal or hepatic impairment and when these interacting drugs are unavoidable.

Indications for Surgery

1. Mechanical symptoms: Large tophi limiting joint motion or tendon function
2. Skin ulceration: Over tophi with risk of secondary infection
3. Secondary infection: Debridement of infected tophi
4. Nerve compression: Carpal tunnel, ulnar neuropathy from tophi
5. Joint destruction: Arthroplasty for end-stage arthropathy
6. Tendon rupture: Repair or reconstruction

Surgical Principles

Disease Complications

• Chronic erosive arthropathy: Joint destruction, subluxation
• Tendon rupture: Achilles, patellar, extensor tendons
• Carpal tunnel syndrome: From tophaceous deposits
• Renal complications: Uric acid stones, urate nephropathy
• Cardiovascular disease: Independent risk factor

Surgical Complications

• Wound healing problems: Skin necrosis, delayed healing over tophi
• Infection: Risk increased with ulcerated tophi
• Recurrence: If ULT not optimized
• Tendon injury: During tophus excision

Global Epidemiology

• Prevalence: ranges from under 1% to 6.8% of adults depending on population (Dehlin et al., Nat Rev Rheumatol 2020). Highest in Taiwanese aboriginal, Maori and Pacific Island populations (often greater than 6-10%), where reduced renal urate excretion and genetic urate-transporter variants combine with diet.
• Incidence: 0.58-2.89 per 1000 person-years; rising worldwide with obesity, ageing and metabolic syndrome.
• Sex/age: male predominance roughly 3-4:1, narrowing after menopause; peaks in men aged 40-60.
• Care gap: only one-third to one-half of patients ever receive urate-lowering therapy, and fewer than half adhere - the dominant problem in gout is implementation, not drug efficacy.

Side-by-side Guideline Comparison

Registry & Surgical Outcome Notes

• There is no dedicated international gout registry equivalent to arthroplasty joint registries, but national arthroplasty registries (NJR UK, AJRR US, AOANJRR Australia, SHAR Sweden) capture gout as a comorbidity. Crystal arthropathy is associated with modestly higher periprosthetic joint infection and wound-complication rates in some series, reinforcing the value of preoperative urate control.
• Hand-surgery series of tophaceous excision report good functional gain but real risks of delayed wound healing and recurrence if ULT is not optimised.

High- vs Limited-Resource Practice Variation

• Well-resourced settings: ready access to polarised microscopy, ultrasound and DECT; HLA-B*58:01 genotyping where indicated; biologic IL-1 inhibitors (anakinra, canakinumab) for refractory disease.
• Limited-resource settings: diagnosis often clinical or via serum urate; polarised microscopy and DECT may be unavailable. Allopurinol and colchicine are inexpensive and on the WHO model essential-medicines landscape, so treat-to-target ULT remains achievable even where advanced imaging is not. Counterfeit colchicine and lack of monitoring are practical hazards.
• Across all settings, cardiovascular and renal risk screening is integral given the strong, consistent association of gout with CKD and cardiovascular disease.

• Febuxostat cardiovascular safety: CARES (29527974) showed higher all-cause and CV mortality with febuxostat versus allopurinol in patients with established CV disease, prompting an FDA boxed warning. The later EMA-mandated FAST trial (33181081) found febuxostat non-inferior with no excess mortality. The discrepancy (high CARES drop-out and on-treatment vs intention-to-treat handling) leaves the true CV risk unresolved; allopurinol remains the pragmatic first-line.
• Asymptomatic hyperuricaemia: routine urate-lowering for asymptomatic hyperuricaemia is not recommended by ACR or EULAR; whether high-risk subgroups (CKD, CV disease) benefit remains debated.
• Start ULT during a flare? ACR 2020 permits initiating allopurinol during an acute flare (with prophylaxis) on the basis it does not prolong the attack; traditional teaching and many other guidelines still defer ULT until the flare settles. Either way, never stop established ULT during a flare.
• Surgery for tophi: timing and technique are not standardised. Wide excision risks unclosable defects; many now favour debulking with optimised ULT to let residual deposits dissolve medically rather than aggressive resection.
• Diet vs drugs: dietary modification lowers urate only modestly (roughly 1 mg/dL); it supports but does not replace ULT, and over-emphasis can stigmatise patients and delay effective treatment.